Cosmos Health Inc.·Healthcare
Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Healthcare
Drug Manufacturers - Specialty & Generic
149
2010-07-23
4.30

Revenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segments Gross profit growing 801% to $71.2M: Margins expanding from 12.1% to 35.5% — driven by a structural shift toward high-margin proprietary segments Net income improving by $50.1M: Transition to profitability in 2027; net income of $31.0 million by 2029 Self-funding growth model: Operating cash flow turning positive in 2027 at $11.9 million, more than doubling to $24.0 million by 2029 Balance sheet transformation: Cash up 18-fold to $62.9 million; all convertible notes repaid; cash anticipated to exceed total debt levels by 2027 Shareholder value: stockholders' equity up 402% to $92.3 million and per-share value creation with EPS of $0.73 by 2029 Clear growth drivers: High-margin proprietary products, expansion of the distribution and manufacturing platform, global partnerships, advancement of the R&D pipeline, AI-driven efficiencies, and disciplined capital allocation — with the U.S. serving as a new growth engine alongside selective M&A activity CHICAGO, May 26, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its financial guidance for the 2026–2029 period. Cosmos Health enters this guidance period following its strongest financial performance in Company history — full year 2025 revenue of $65.3 million, up 20% year-over-year, with gross profit increasing 83%, gross margin expanding 418 basis points, and cash rising more than tenfold to $3.5 million.

No dilution to existing shareholders Reduction in total outstanding warrant overhang Simplifies capital structure CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Series B warrants expired unexercised in accordance with their original terms at 5:00 p.m. New York City time on May 19, 2026.

Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segments Total liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balances Stockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis points Adjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growth Record momentum continues into Q2 2026 with U.S. expansion actively underway CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Income Statement Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength - over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.

Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program €25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D program Institutional-grade capital: Potential long-term, attractively structured financing from the EU's premier development bank R&D acceleration: Strengthens and expands the Company's development pipeline across its portfolio Value creation catalyst: Landmark funding opportunity supporting long-term innovation and growth CHICAGO, IL / ACCESS Newswire / May 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories, it is pursuing a strategic research and development (R&D) financing program with the European Investment Bank (EIB), the financing arm of the European Union and one of the world's largest multilateral lenders. In connection with this initiative, Cana Laboratories has entered into an advisory agreement with the EIB to support the Company's progress under the EIB-backed financing program.

CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a request for withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-283910), originally filed on December 18, 2024 and last amended on June 3, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.

CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is projecting Fort18™ to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions. Fort18™ is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products.